DB
BBIO icon

Danske Bank’s BridgeBio Pharma BBIO Stock Holding History

Danske Bank’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.9K Sell
200
-1,800
-90% -$130K ﹤0.01% 759
2025
Q4 		$153K Hold
2,000
– – ﹤0.01% 702
2025
Q3 		$104K Hold
2,000
– – ﹤0.01% 855
2025
Q2 		$86.4K Buy
+2,000
New +$72.7K ﹤0.01% 886

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Danske Bank's BBIO Position: Q1 2026 in Review

Danske Bank reduced its BridgeBio Pharma (BBIO) stake by 90% in Q1 2026, selling an estimated $130K and leaving 200 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Danske Bank first reported a position in BBIO in Q2 2025 and has held it in 4 quarters since. The position peaked at $153K in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Danske Bank held 200 shares of BridgeBio Pharma worth $14.9K as of Q1 2026.
  • Danske Bank sold 1,800 BridgeBio Pharma shares in Q1 2026, an estimated $130K.
  • BridgeBio Pharma made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #759 holding.
  • Danske Bank first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 4 quarters since.
  • Danske Bank's BridgeBio Pharma position peaked at $153K in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.